Maravai Completes $1.863 Billion Initial Public Offering
Summary
Baird transaction summary stating that Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a portfolio company of GTCR, LLC, completed an initial public offering of 69,000,000 shares of Class A common stock at $27.00 per share, generating gross proceeds of approximately $1.863 billion. It says the amount included the exercise in full by the underwriters of their option to purchase 9,000,000 additional shares, and that Baird served as a book-running manager. The transaction is dated November 2020. It states that GTCR has invested more than $18 billion in over 200 companies since its inception.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Maravai Completes $1.863 Billion Initial Public Offering.”
Original at www.rwbaird.com. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/baird-maravai-ipo-transaction-summary-acfa2b3e75/
, SHA-256 eede9ac76a58285a11cc8ac675707cf22337d27c0301eca46f127c222bcaa913.Full text
Deal Details Maravai Completes $1.863 Billion Initial Public Offering Healthcare Maravai initial public offering Summary Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI), a portfolio company of GTCR, LLC (“GTCR”), recently completed an initial public offering of 69,000,000 shares of its Class A common stock at $27.00 per share, generating gross proceeds of approximately $1.863 billion, which included the exercise in full by the underwriters of their option to purchase 9,000,000 additional shares of Class A common stock on the same terms and conditions. Baird served as a book-running manager on this offering. About Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. Maravai LifeSciences Holdings, Inc. is headquartered in San Diego, California. Founded in 1980, GTCR is a leading growth-oriented private equity firm focused on investing in growth companies in the Healthcare, Financial Services & Technology, Technology, Media & Telecommunications and Growth Business Services industries. GTCR pioneered The Leaders Strategy™—finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Maravai is an example of the Leaders Strategy™, whereby GTCR is partnering with Carl Hull and Eric Tardif to build and grow a leading life sciences platform. Since its inception, GTCR has invested more than $18 billion in over 200 companies. GTCR is headquartered in Chicago, Illinois. CONTACT US TO LEARN MORE Healthcare Maravai initial public offering Date November 2020 Company Maravai LifeSciences Holdings, Inc. Transaction Equity Capital Markets Sectors Healthcare Verticals Life Sciences Tools & Diagnostics Target Geography North America Share See All Transactions Similar Transactions Healthcare Upperton investment from Inflexion Healthcare Geron follow-on offering Healthcare Apellis follow-on offering Healthcare Blue Cloud , a portfolio company of Norwest , sale to The Rise Fund
File and source
- File
- baird-maravai-ipo-transaction-summary.html
- Size
- 60,005 bytes
- SHA-256
- eede9ac76a58285a11cc8ac675707cf22337d27c0301eca46f127c222bcaa913
- Original
- www.rwbaird.com